Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 24 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Keyword is Diabetic Nephropathies [Clear All Filters]
Combination therapy with an SGLT-2 inhibitor and finerenone in DKD: Are we there yet?.
Eur J Clin Invest. 53(2), e13864.
(2023). Frailty, sarcopenia and diabetic kidney disease: where do we stand?.
Int Urol Nephrol. 55(5), 1173-1181.
(2023). Therapeutic Advances in Diabetic Kidney Disease..
Int J Mol Sci. 24(3),
(2023). Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial..
Lancet. 393(10184), 1937-1947.
(2019). The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials..
J Hypertens. 37(7), 1334-1343.
(2019). SGLT-2 inhibitors in Diabetic Kidney Disease: What Lies Behind their Renoprotective Properties?.
Curr Med Chem. 26(29), 5564-5578.
(2019). Association of ALOX12 gene polymorphism with all-cause and cardiovascular mortality in diabetic nephropathy..
Int Urol Nephrol. 50(2), 321-329.
(2018). The contribution of genetic variants of SLC2A1 gene in T2DM and T2DM-nephropathy: association study and meta-analysis..
Ren Fail. 40(1), 561-576.
(2018). Mineralocorticoid Receptor Antagonists for Nephroprotection: Current Evidence and Future Perspectives..
Curr Pharm Des. 24(46), 5528-5536.
(2018). Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study..
Am J Med. 130(12), 1465.e27-1465.e39.
(2017). The effect of SGLT2 inhibitors on cardiovascular events and renal function..
Expert Rev Clin Pharmacol. 10(11), 1251-1261.
(2017). Matrix Gelatinases in Atherosclerosis and Diabetic Nephropathy: Progress and Challenges..
Curr Vasc Pharmacol. 15(6), 557-565.
(2017). Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation?.
Kidney Int. 85(3), 536-46.
(2014). Combined angiotensin inhibition in diabetic nephropathy..
N Engl J Med. 370(8), 778-9.
(2014). TNF-α and microalbuminuria in patients with type 2 diabetes mellitus..
J Diabetes Res. 2014, 394206.
(2014). Uric acid, chronic kidney disease and type 2 diabetes: a cluster of vascular risk factors..
J Diabetes Complications. 28(2), 122-3.
(2014). The renal endothelium in diabetic nephropathy..
Ren Fail. 35(4), 592-9.
(2013). Glomerular filtration rate estimation in patients with type 2 diabetes: creatinine- or cystatin C-based equations?.
Diabetologia. 54(12), 2987-94.
(2011). PPAR-γ agonism for cardiovascular and renal protection..
Cardiovasc Ther. 29(6), 377-84.
(2011). Diabetic nephropathy: Endothelin antagonism for diabetic nephropathy..
Nat Rev Nephrol. 6(8), 447-9.
(2010). Effect of ramipril alone compared to ramipril with eplerenone on diabetic nephropathy in streptozocin-induced diabetic rats..
Pharmacology. 86(2), 85-91.
(2010). Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis..
Am J Kidney Dis. 55(5), 835-47.
(2010). Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy..
Expert Opin Pharmacother. 11(5), 723-30.
(2010). A tumor-like manifestation of extrapulmonary tuberculosis in a hemodialysis patient..
Clin Nephrol. 71(6), 714-8.
(2009).